Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Our understanding is limited concerning the tumor immune microenvironment of inflammatory breast cancer (IBC), an aggressive form of primary cancer with low rates of pathologic complete response to current neoadjuvant chemotherapy (NAC) regimens. We retrospectively identified pretreatment (N = 86) and matched posttreatment tissue (N = 27) from patients with stage III or de novo stage IV IBC who received NAC followed by a mastectomy. Immune profiling was performed including quantification of lymphoid and myeloid infiltrates by IHC and T-cell repertoire analysis. Thirty-four of 86 cases in this cohort (39.5%) achieved a pathologic complete response. Characterization of the tumor microenvironment revealed that having a lower pretreatment mast cell density was significantly associated with achieving a pathologic complete response to NAC (P = 0.004), with responders also having more stromal tumor-infiltrating lymphocytes (P = 0.035), CD8+ T cells (P = 0.047), and CD20+ B cells (P = 0.054). Spatial analysis showed close proximity of mast cells to CD8+ T cells, CD163+ monocytes/macrophages, and tumor cells when pathologic complete response was not achieved. PD-L1 positivity on tumor cells was found in fewer than 2% of cases and on immune cells in 27% of cases, but with no correlation to response. Our results highlight the strong association of mast cell infiltration with poor response to NAC, suggesting a mechanism of treatment resistance and a potential therapeutic target in IBC. Proximity of mast cells to immune and tumor cells may suggest immunosuppressive or tumor-promoting interactions of these mast cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, B cells have previously been shown to be positively associated with responses to chemotherapy in other cancer types39,40.”
From B cells and tertiary lymphoid structures promote immunotherapy response (2020) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
spatstat: An R Package for Analyzing Spatial Point Patterns
Baddeley, A., & Turner, R. (2005) · Journal of Statistical Software · doi:10.18637/jss.v012.i06 · Cited by 2,328
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · cited 6×
“We showed expected biomarkers of response to NAC such as TILs and CD8þ T-cell infiltrate, which have a known role across solid tumors in shaping response to therapy.”
ResultInfluentialPembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Mast cells as sources of cytokines, chemokines, and growth factors
Mukai, K., Tsai, M., Saito, H., & Galli, S. J. (2018) · Immunological Reviews · doi:10.1111/imr.12634 · Cited by 682
Theoharides, T. C., Alysandratos, K.-D., Angelidou, A., Delivanis, D.-A., Sismanopoulos, N., Zhang, B., Asadi, S., Vasiadi, M., Weng, Z., Miniati, A., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.014 · Cited by 680
Carstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633
Self-citationHistamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors
Jutel, M., Watanabe, T., Klunker, S., Akdis, M., Thomet, O. A. R., Malolepszy, J., Zak-Nejmark, T., Koga, R., Kobayashi, T., Blaser, K., et al. (2001) · Nature · doi:10.1038/35096564 · Cited by 587
Research works printed but not linked: 1
- Rugo, Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8–12; San Antonio, TX
Cited by
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationTowards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 363
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Somasundaram, R., Connelly, T., Choi, R., Choi, H., Samarkina, A., Li, L., Gregorio, E., Chen, Y., Thakur, R., Abdel-Mohsen, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20600-7 · Cited by 185
Self-citationMast Cells in the Tumor Microenvironment
Aponte-López, A., & Muñoz-Cruz, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-49270-0_9 · Cited by 172
Mast Cells: A New Frontier for Cancer Immunotherapy
Lichterman, J. N., & Reddy, S. M. (2021) · Cells · doi:10.3390/cells10061270 · Cited by 172
Self-citation
Metadata
- Authors
- Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., Tsujikawa, T., Coussens, L. M., Wani, K., He, Y., Villareal, L., Wood, A., Rao, A., Woodward, W. A., Ueno, N. T., Krishnamurthy, S., Wargo, J. A., & Mittendorf, E. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Michigan (US)
- Oregon Health & Science University (US)
- 11Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas.
- Brigham and Women's Hospital (US)
- Corresponding author
- Krishnamurthy, Savitri
- Wargo, Jennifer A.
- Mittendorf, Elizabeth A.
- ORCID
- Reddy, Sangeetha M.
- Reuben, Alexandre
- Barua, Souptik
- Jiang, Hong
- Zhang, Shaojun
- Wang, Linghua
- Gopalakrishnan, Vancheswaran
- Hudgens, Courtney W.
- Tetzlaff, Michael T.
- Reuben, James M.
- Tsujikawa, Takahiro
- Coussens, Lisa M.
- Wani, Khalida
- Rao, Arvind
- Woodward, Wendy A.
- Ueno, Naoto T.
- Krishnamurthy, Savitri
- Wargo, Jennifer A.
- Mittendorf, Elizabeth A.
- Venue
- Cancer Immunology Research
- Published
- 2019-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 1025-1035
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC7053657
- OpenAlex
- W2942793545
- Cited by
- 106
- References
- 53
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 15 · 2020: 15 · 2019: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Breast Cancer Research Foundation Conquer Cancer Foundation
- Breast Cancer Research Foundation
- Morgan Welch Inflammatory Breast Cancer ResearchState of Texas Rare and Aggressive Breast Cancer ResearchMD Anderson Cancer Center NCI (CA16672)
- NIH (T32 CA 009666)
- Kimberley Clark Foundation
- CCSG (P30 CA016672)
- University of Texas MD Anderson Cancer Center
- CPRIT (RP170719, RP150578)
- NCI (R01CA214955-01A1)
- American Cancer Society (RSG-16-005-01)
- Pink Ribbons Project
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- inflammatory breast cancer, neoadjuvant chemotherapy response, mast cell infiltration, tumor immune microenvironment, pathological complete response, tumor-infiltrating lymphocytes, CD8+ T cells, CD20+ B cells, CD163+ macrophages, PD-L1, treatment resistance, spatial analysis
- MeSH terms
- Adult, Aged, Histocompatibility Antigens Class II, Female, Humans, Macrophages, Mast Cells, Middle Aged, Neoplasm Staging, Prognosis, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Young Adult, Inflammatory Breast Neoplasms, Tumor Microenvironment, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0619
- The paper
- Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., Tsujikawa, T., Coussens, L. M., Wani, K., He, Y., Villareal, L., Wood, A., Rao, A., Woodward, W. A., Ueno, N. T., . . . Mittendorf, E. A. (2019). Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.